ArticleGenome medicine2026
Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundPathogenic germline variants in DNA damage response and repair (DDR) genes are established risk factors for prostate cancer (PrCa). Genetic testing for inherited PrCa is usually limited to small gene panels, even though common variants are recognised as harbouring a significant proportion of heritable risk. We have developed a genetic test to identify individuals with a genetic predisposition to PrCa from rare and/or common risk variants, with added potential to inform clinical management of PrCa patients, by detecting targets for personalised treatment, and gather further evidence for candidate genes.
methodsGermline genetic testing was offered to 1095 PrCa patients, as part of a research study, to inform on genetic predisposition and determine eligibility for personalised treatment options. Targeted sequencing of 117 DDR genes and HOXB13 was performed together with genotyping of 130–396 common PrCa risk variants. This test we have called PRODICT. Genetic reports were provided to participants including (A) rare variant status and (B) polygenic risk score (PRS).
resultsPathogenic or likely pathogenic (P/LP) variants were detected in 16.7% of cases, most frequently in MUTYH (2.5%), CHEK2 (2.2%), ATM (1.4%) and BRCA2 (1.3%) and 46.0% of study participants had a PRS in the top quintile of the risk distribution. Univariate analyses of the predominantly European cohort showed that carriers of P/LP variants in PrCa predisposition genes were more likely to be Grade Group ≥ 4 (odds ratio (OR) = 4.57, 95% confidence interval (CI) = 1.33–15.73, p = 0.02) and have metastatic disease (OR = 2.12, 95% CI = 1.09–4.12, p = 0.03), however, once all genes with a P/LP variant were included in the analysis, the associations were not statistically significant. Carriers of a P/LP variant in any DDR gene, were more likely to have a PRS in the bottom quintile of the risk distribution than the top, compared to non-carriers (OR = 2.39, 95% CI = 1.17–4.89, p = 0.02). Overall, based on the PRODICT test, we found that 48.3% of study participants had increased germline genetic predisposition to PrCa.
conclusionsOur single germline genetic test for rare and common risk variants, identifies a significant number of individuals with a genetic predisposition to PrCa and has potential to inform clinical decision making for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.